The Fort Worth Press - Bayer proposes class settlement for weedkiller cancer claims

Under the proposed agreement, Monsanto would make a series of declining annual payments for up to 21 years, Bayer said, adding that the deal still required court approval.

Bayer has spent more than $10 billion settling thousands of cases linked to Roundup since it acquired its producer, the US agrochemical group Monsanto, in 2018.

The International Agency for Research on Cancer considers glyphosate, one of Roundup's ingredients, a probable human carcinogen, but Bayer says scientific studies and regulatory approvals show the weedkiller is safe.

The US Supreme Court in January agreed to hear Bayer's appeal against an award of $1.25 million to a Missouri man who claimed Roundup was responsible for his blood cancer.

The company argues that it should be shielded from state lawsuits since the federal Environmental Protection Agency (EPA) approved the sale of Roundup to US consumers and farmers without any warnings.

"The proposed class settlement agreement, together with the Supreme Court case, provides an essential path out of the litigation uncertainty," Bayer CEO Bill Anderson said in a statement.

"This litigation and the resulting cost underscore the need for guidance from the Supreme Court on clear regulation in American agriculture," he added.

Bayer shares surged after the announcement and were the best performer on Germany's bluechip DAX index, up 7.35 percent.

- 67,000 cases outstanding -

Getting the settlement through would mark a milestone for Bayer, which otherwise faces a potentially still long and expensive legal road.

About 67,000 Roundup cases are still outstanding and Anderson told the Wall Street Journal last year that Bayer might give up on Roundup, the world's most popular weedkiller, citing the cost of prolonged court battles.

Announcing that it had reached separate settlements for some Roundup cases as well as other disputes, Bayer said it was now setting aside 11.8 billion euros to pay for litigation in its business year to end September 2025, up from 7.8 billion previously.

Bayer expected litigation payouts of about five billion euros for 2026 "on a first estimate", it said, adding that it would delay announcing its financial results and 2026 guidance from February 25 to March 4.

The settlements did not contain or imply any admission of liability or wrongdoing, Bayer added.

T.M.Dan--TFWP